Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela; R. Jake Jacobs; Oscar Arteaga; Maria S. Navarrete; Allen S. Meyerhoff; Bruce L. Innis

doi:10.1016/j.vaccine.2005.03.021

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela, R. Jake Jacobs, Oscar Arteaga, Maria S. Navarrete, Allen S. Meyerhoff, Bruce L. Innis

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

Original language	American English
Pages (from-to)	4110-4119
Number of pages	10
Journal	Vaccine
Volume	23
Issue number	32
DOIs	https://doi.org/10.1016/j.vaccine.2005.03.021
State	Published - 14 Jul 2005
Externally published	Yes

Keywords

Cost and cost analysis
Hepatitis A
Vaccination

Access to Document

10.1016/j.vaccine.2005.03.021

Fingerprint Dive into the research topics of 'Cost-effectiveness of universal childhood hepatitis A vaccination in Chile'. Together they form a unique fingerprint.

Cite this

@article{ef15333f90714938b8efc3cddc624f86,

title = "Cost-effectiveness of universal childhood hepatitis A vaccination in Chile",

abstract = "Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.",

keywords = "Cost and cost analysis, Hepatitis A, Vaccination, Cost and cost analysis, Hepatitis A, Vaccination",

author = "Valenzuela, {M. Teresa} and Jacobs, {R. Jake} and Oscar Arteaga and Navarrete, {Maria S.} and Meyerhoff, {Allen S.} and Innis, {Bruce L.}",

year = "2005",

month = jul,

day = "14",

doi = "10.1016/j.vaccine.2005.03.021",

language = "American English",

volume = "23",

pages = "4110--4119",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "32",

}

TY - JOUR

T1 - Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

AU - Valenzuela, M. Teresa

AU - Jacobs, R. Jake

AU - Arteaga, Oscar

AU - Navarrete, Maria S.

AU - Meyerhoff, Allen S.

AU - Innis, Bruce L.

PY - 2005/7/14

Y1 - 2005/7/14

N2 - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

AB - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

KW - Cost and cost analysis

KW - Hepatitis A

KW - Vaccination

KW - Cost and cost analysis

KW - Hepatitis A

KW - Vaccination

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=20444436017&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=20444436017&origin=inward

U2 - 10.1016/j.vaccine.2005.03.021

DO - 10.1016/j.vaccine.2005.03.021

M3 - Article

VL - 23

SP - 4110

EP - 4119

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -